Zogenix and Purdue Pharma exchange waivers of regulatory exclusivity for ER hydrocodone
Zogenix announced an agreement with Purdue Pharma whereby the two companies have exchanged waivers of regulatory exclusivity applicable to their respective single-entity, extended-release hydrocodone products. These waivers are applicable to current or pending NDAs as well as successor products. October 31, 2014